Questions? Call us at +45 25 32 17 73


Meet us at The 4BIO Summit in London

At the qPCR & Digital Congress Anapa Biotech will present a poster entitled "MeltPlex multiplex PCR" at position q8. The poster presentation describes the design of MeltPlex® probes targeting 17 different hemorrhagic fever viruses in a single PCR tube and the results of testing against artificial DNA targets.


Anapa Biotech has developed the MeltPlex® technology that utilizes a system of labelled Taqman-type probes allowing each to be read out by subsequent melting curve analysis. 5 or more probes can now be analyzed per fluorophore channel totaling more than 20 targets per single tube.

Despite the developments in conventional PCR, the complexity of multiplex Real Time PCR is still limited due to the lack of sufficient detection channels. This promted the development of MeltPlex®, which expands the multiplexing limits of PCR diagnostics.

“With MeltPlex®, we enable considerably more answers per sample as well as more cost-efficient diagnostic processing,” says Søren Morgenthaler Echwald, CEO of Anapa Biotech and adds “In particular, with MeltPlex® we are opening new opportunities for design of syndromic PCR panels covering up to 20 or more pathogens, on the existing installed base of both stand-alone and sample-to-result real-time PCR instruments."

MeltPlex® reaction and melting analysis is performed without the need to re-open PCR reaction tubes. By utilizing melting curve readout of modified probes – one for each target - rather than the only amplicons, the system also adds an extra level of specificity to melting curve analysis.

MeltPlex® is covered by patent applications by Anapa Biotech and is available for licensing.


Meet us at the congress at position q8, see the poster and please contact Anapa Biotech for more information:

CEO Søren Morgenthaler Echwald, + 45 2264 4916, This email address is being protected from spambots. You need JavaScript enabled to view it.



Anapa Biotech A/S, former QuantiBact A/S, develops molecular tools to enhance the performance of natural nucleic acids in PCR based assays as well as hybridization. Our technology offers improvement to areas like human and veterinary diagnostics, food and feed quality and safety, environmental surveillance and general scientific research. For more information, visit the new website at



Vecata Invest A/S is an investment company managing the venture investments of the Bagger-Sorensen Group. The company invests primarily in Life Science, IT, and technology companies. For more information, visit their website at